Research map: Interpretation of the BRIGHT-2 Trial—Reply

Back to the article

Papers in this map

  1. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer · Stephen R.D. Johnston · 2019 · 695 citations · Cited by this paper
  2. Considerations in Genomic Therapy Matching—Reply · 2026 · Related
  3. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial · Binghe Xu · 2021 · 185 citations · Cited by this paper
  4. Survival Language · 2026 · Related
  5. Expert consensus on treating HR+/HER2- metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists · Hope S. Rugo · 2025 · 5 citations · Cited by this paper
  6. A Dermatologist’s Perspective on Cutaneous Adverse Effects in CTCAE Version 6.0 · 2026 · Related
  7. Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression · Jiayu Wang · 2026 · 4 citations · Cited by this paper
  8. Global Consensus on the Management of Primary Localized Chordoma · 2026 · Related
  9. Safety and tolerability of bireociclib for the treatment of advanced solid tumors as monotherapy and in combination with endocrine therapy: a multicenter, open-label, phase 1 clinical trial · Jiayu Wang · 2025 · 2 citations · Cited by this paper
  10. Survival in the SONIA Trial—Reply · 2026 · Related
  11. When TNM Staging Is Not Sufficient · 2026 · Related
  12. Transarterial Chemoembolization Plus Thermal Ablation in Unresectable Hepatocellular Carcinoma · 2026 · Related
  13. Treatment Delays in Early Age–Onset Colorectal Cancer · 2026 · Related
  14. Fluids for Immune Checkpoint Inhibitor Diabetic Ketoacidosis—Reply · 2026 · Related
  15. Interpretation of the BRIGHT-2 Trial · 2026 · Related

Source: OpenAlex (CC0)